Lupin Limited (NSE:LUPIN)
1,976.70
-3.60 (-0.18%)
Nov 16, 2026, 3:29 PM IST
Lupin Revenue
Lupin had revenue of 78.27B INR in the quarter ending September 30, 2026, with 11.06% growth. This brings the company's total for the last twelve months to 307.46B, up 24.22% year-over-year. In the fiscal year ending March 31, 2026, Lupin had annual revenue of 279.58B with 23.12% growth.
Revenue (ttm)
307.46B
Revenue Growth
+24.22%
P/S Ratio
2.93
Revenue / Employee
11.82M
Employees
26,021
Market Cap
901.90B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Lupin breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 279.58B | 52.50B | 23.12% |
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 369.13B |
| Zydus Lifesciences | 303.78B |
| Cipla | 279.89B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 156.32B |
| Mankind Pharma | 153.79B |
| Ipca Laboratories | 104.80B |
| Emcure Pharmaceuticals | 102.34B |
Lupin News
- 12 days ago - Lupin Transcript: Q2 26/27 - Transcripts
- 12 days ago - Lupin Quarterly report: Q2 2027 - Filings
- 12 days ago - Lupin Slides: Q2 2027 - Filings
- 5 weeks ago - Lupin Secures FDA Nod For Vitamin K Injection - Nasdaq
- 6 weeks ago - Lupin Secures Tentative FDA Nod For Apixaban Oral Suspension - Nasdaq
- 2 months ago - Lupin Gets FDA Approval For Modafinil Tablets - Nasdaq
- 2 months ago - Lupin And Tenpoint Partner To Expand YUVEZZI In Europe - Nasdaq
- 3 months ago - Lupin Secures FDA Approval For Pitolisant Tablets, Generic Of WAKIX; Expects Launch In 2030 - Nasdaq